NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Jeffrey Segal MD, JD, a medico-legal expert and the founder of Medical Justice, discussed the shifting dynamics of the market for GLP-1 receptor agonist medications in a recent blog, “The Whirlwind ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Stocks, bonds and the dollar saw small moves, with traders unwilling to make any significant bets as they await key inflation data for clues on whether the Federal Reserve will cut or hold rates next ...

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...

A NEW weight loss jabs dubbed the “King Kong” is set to hit the Irish market as soon as next year. Mounjaro can be used to ...

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The biopharmaceutical industry faces ongoing regulatory challenges, and Eli Lilly is no exception. The potential impact of the International Pricing Index (IPI) on the company's pricing power ...

No one else can do that. They aren’t rich enough. The GLP-1s, they represent value because it’s not just about diabetes and weight loss, they’re lifesavers… GLP-1’s not some simple hack ...

Shares of healthcare company Hims & Hers Health (HIMS) surged on Thursday after a Texas court temporarily paused a case involving the FDA’s decision to end the shortage status of Eli Lilly’s ...

blockbuster type 2 diabetes and weight loss drug tirzepatide was no longer in shortage. Despite closing the case, however, the FDA said it is "carefully assessing the challenged decision and ...